Načítá se...
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
AIMS: Canagliflozin is a sodium glucose co-transporter 2 inhibitor in development for treatment of type 2 diabetes mellitus (T2DM). This study evaluated the efficacy and safety of canagliflozin in subjects with T2DM and stage 3 chronic kidney disease [CKD; estimated glomerular filtration rate (eGFR)...
Uloženo v:
| Hlavní autoři: | , , , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Blackwell Publishing Ltd
2013
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3654568/ https://ncbi.nlm.nih.gov/pubmed/23464594 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12090 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|